Patent · US Active

Induction of cross-reactive cellular response against rhinovirus antigens

US9937252B2 · kind B2 · utility

0Cited by
0References
15Claims
0Family size

Inventors

Key dates

Filing dateFeb 6, 2014
Grant dateApr 10, 2018
Priority date
Expiry dateFeb 6, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2770/32734
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.